WallStreetZenWallStreetZen

NYSEMKT: NSRX
Nasus Pharma Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for NSRX

Based on 2 analysts offering 12 month price targets for Nasus Pharma Ltd

Min Forecast
$18.00+522.84%
Avg Forecast
$18.50+540.14%
Max Forecast
$19.00+557.44%

Should I buy or sell NSRX stock?

Based on 2 analysts offering ratings for Nasus Pharma Ltd.

Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their NSRX stock forecasts and price targets.

NSRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-26
lockedlocked$00.00+00.00%2025-12-18

1 of 1

Forecast return on equity

Is NSRX forecast to generate an efficient return?

Company
-448.49%
Industry
18.21%
Market
159.23%
NSRX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NSRX forecast to generate an efficient return on assets?

Company
-248.09%
Industry
26.04%
NSRX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NSRX earnings per share forecast

What is NSRX's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$1.65
Avg 2 year Forecast
-$1.49
Avg 3 year Forecast
-$1.38

NSRX revenue forecast

What is NSRX's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$7.3M

NSRX vs General Drug Manufacturer Stocks

TickerPricePrice TargetUp/downsideConsensus
NSRX$2.89$18.50+540.14%Buy
MDCX$0.30$9.00+2,890.03%Strong Buy
MIRA$0.96N/AN/A
SCLX$6.29N/AN/A
AMRN$14.56N/AN/A
View Top General Drug Manufacturer Stocks

Nasus Pharma Stock Forecast FAQ

Is Nasus Pharma Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NYSEMKT: NSRX) stock is to Buy NSRX stock.

Out of 2 analysts, 0 (0%) are recommending NSRX as a Strong Buy, 2 (100%) are recommending NSRX as a Buy, 0 (0%) are recommending NSRX as a Hold, 0 (0%) are recommending NSRX as a Sell, and 0 (0%) are recommending NSRX as a Strong Sell.

If you're new to stock investing, here's how to buy Nasus Pharma stock.

What is NSRX's earnings growth forecast for 2026-2028?

(NYSEMKT: NSRX) Nasus Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 49.82%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 68.66%.

Nasus Pharma's earnings in 2026 is -$5,856,000.On average, 4 Wall Street analysts forecast NSRX's earnings for 2026 to be -$14,892,511, with the lowest NSRX earnings forecast at -$19,613,867, and the highest NSRX earnings forecast at -$9,646,460. On average, 4 Wall Street analysts forecast NSRX's earnings for 2027 to be -$13,462,671, with the lowest NSRX earnings forecast at -$15,814,785, and the highest NSRX earnings forecast at -$10,772,481.

In 2028, NSRX is forecast to generate -$12,414,182 in earnings, with the lowest earnings forecast at -$11,927,352 and the highest earnings forecast at -$12,779,305.

What is NSRX's revenue growth forecast for 2026-2028?

(NYSEMKT: NSRX) Nasus Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.58%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 16.62%.

Nasus Pharma's revenue in 2026 is $0.On average, 4 Wall Street analysts forecast NSRX's revenue for 2026 to be $0, with the lowest NSRX revenue forecast at $0, and the highest NSRX revenue forecast at $0. On average, 3 Wall Street analysts forecast NSRX's revenue for 2027 to be $0, with the lowest NSRX revenue forecast at $0, and the highest NSRX revenue forecast at $0.

In 2028, NSRX is forecast to generate $65,749,188 in revenue, with the lowest revenue forecast at $63,170,789 and the highest revenue forecast at $67,687,496.

What is NSRX's forecast return on assets (ROA) for 2026-2028?

(NYSEMKT: NSRX) forecast ROA is -248.09%, which is lower than the forecast US Drug Manufacturers - General industry average of 26.04%.

What is NSRX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year NSRX price target, the average NSRX price target is $18.50, with the highest NSRX stock price forecast at $19.00 and the lowest NSRX stock price forecast at $18.00.

On average, Wall Street analysts predict that Nasus Pharma's share price could reach $18.50 by Mar 26, 2027. The average Nasus Pharma stock price prediction forecasts a potential upside of 540.14% from the current NSRX share price of $2.89.

What is NSRX's Earnings Per Share (EPS) forecast for 2026-2028?

(NYSEMKT: NSRX) Nasus Pharma's current Earnings Per Share (EPS) is -$0.72. On average, analysts forecast that NSRX's EPS will be -$1.65 for 2026, with the lowest EPS forecast at -$2.18, and the highest EPS forecast at -$1.07. On average, analysts forecast that NSRX's EPS will be -$1.49 for 2027, with the lowest EPS forecast at -$1.75, and the highest EPS forecast at -$1.19. In 2028, NSRX's EPS is forecast to hit -$1.38 (min: -$1.32, max: -$1.42).

What is NSRX's forecast return on equity (ROE) for 2026-2028?

(NYSEMKT: NSRX) forecast ROE is -448.49%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.